NASDAQ:INSM - Insmed Stock Price, Forecast & News

Insmed trades on the NASDAQ under the ticker symbol "INSM."

Insmed Incorporated (NASDAQ:INSM) posted its quarterly earnings results on Wednesday, October, 30th. The biopharmaceutical company reported ($0.68) EPS for the quarter, missing the Zacks' consensus estimate of ($0.67) by $0.01. The biopharmaceutical company earned $38.89 million during the quarter, compared to analyst estimates of $35.89 million. Insmed had a negative return on equity of 114.68% and a negative net margin of 291.19%. During the same quarter last year, the business posted ($1.14) earnings per share. View Insmed's Earnings History.

Insmed is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Insmed.

Insmed will be holding an earnings conference call on Tuesday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

7 Wall Street analysts have issued 12 month price objectives for Insmed's shares. Their forecasts range from $20.00 to $56.00. On average, they anticipate Insmed's share price to reach $43.43 in the next twelve months. This suggests a possible upside of 39.0% from the stock's current price. View Analyst Price Targets for Insmed.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Insmed.

News stories about INSM stock have trended somewhat negative recently, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Insmed earned a news impact score of -1.8 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Insmed.

Insmed saw a decrease in short interest in January. As of January 31st, there was short interest totalling 12,940,000 shares, a decrease of 8.6% from the January 15th total of 14,150,000 shares. Based on an average trading volume of 946,400 shares, the days-to-cover ratio is currently 13.7 days. Currently, 15.3% of the company's shares are sold short. View Insmed's Current Options Chain.

Some companies that are related to Insmed include Mylan (MYL), Beigene (BGNE), Ono Pharmaceutical (OPHLF), Bausch Health Companies (BHC), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Catalent (CTLT), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Dr.Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), ACADIA Pharmaceuticals (ACAD), Reata Pharmaceuticals (RETA), The Medicines (MDCO) and Horizon Therapeutics (HZNP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include AbbVie (ABBV), Geron (GERN), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), Incyte (INCY), Capstone Turbine (CPST), NVIDIA (NVDA), Bausch Health Companies (BHC), CHIMERA INVT CO/SH NEW (CIM) and Johnson & Johnson (JNJ).

Insmed's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), Janus Henderson Group PLC (13.06%), Palo Alto Investors LP (7.67%), Eagle Asset Management Inc. (1.69%), Geode Capital Management LLC (1.36%) and Fairmount Funds Management LLC (1.11%). Company insiders that own Insmed stock include Alfred Altomari, Donald J Hayden Jr, John Goll, Melvin Md Sharoky, Orlov S Nicole Schaeffer, Roger Adsett, Steinar J Engelsen and William Lewis. View Institutional Ownership Trends for Insmed.

INSM stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Bank of America Corp DE, Point72 Asset Management L.P., Marshall Wace LLP, Palo Alto Investors LP, Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust and Rafferty Asset Management LLC. Company insiders that have sold Insmed company stock in the last year include Alfred Altomari, Donald J Hayden Jr, John Goll, Orlov S Nicole Schaeffer and William Lewis. View Insider Buying and Selling for Insmed.

INSM stock was purchased by a variety of institutional investors in the last quarter, including Fairmount Funds Management LLC, FMR LLC, Goldman Sachs Group Inc., Lord Abbett & CO. LLC, AXA, California Public Employees Retirement System, Geode Capital Management LLC and Franklin Resources Inc.. Company insiders that have bought Insmed stock in the last two years include Melvin Md Sharoky, Roger Adsett, Steinar J Engelsen and William Lewis. View Insider Buying and Selling for Insmed.

Shares of INSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of INSM stock can currently be purchased for approximately $31.25.

Insmed has a market capitalization of $2.79 billion and generates $9.84 million in revenue each year. The biopharmaceutical company earns $-324,280,000.00 in net income (profit) each year or ($4.17) on an earnings per share basis. Insmed employs 373 workers across the globe.View Additional Information About Insmed.

The official website for Insmed is http://www.insmed.com/.

Insmed's mailing address is 10 Finderne Avenue Building 10, Bridgewater NJ, 08807. The biopharmaceutical company can be reached via phone at 908-977-9900 or via email at [email protected]